Merck (MRK) said Monday it has dosed the first patient in a phase 3 study assessing ifinatamab deruxtecan against chemotherapy in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma with disease progression after treatment with a platinum-containing systemic therapy and an immune checkpoint inhibitor.
The company said ifinatamab deruxtecan is being jointly developed with Daiichi Sankyo, which discovered the antibody drug conjugate.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.